The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Koen K. A. Van Rompay

California National Primate Research Center

University of California

Davis

CA 95616

USA

[email]@ucdavis.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • California National Primate Research Center, University of California, Davis, CA 95616, USA. 1996 - 2012
  • Sahaya International Inc., Davis, USA. 2008
  • University of California, Davis, USA. 2004

References

  1. Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. Van Rompay, K.K., Trott, K.A., Jayashankar, K., Geng, Y., LaBranche, C.C., Johnson, J.A., Landucci, G., Lipscomb, J., Tarara, R.P., Canfield, D.R., Heneine, W., Forthal, D.N., Montefiori, D., Abel, K. Retrovirology (2012) [Pubmed]
  2. Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques. Van Rompay, K.K., Babusis, D., Abbott, Z., Geng, Y., Jayashankar, K., Johnson, J.A., Lipscomb, J., Heneine, W., Abel, K., Ray, A.S. Antimicrob. Agents Chemother. (2012) [Pubmed]
  3. Evaluation of antiretrovirals in animal models of HIV infection. Van Rompay, K.K. Antiviral Res. (2010) [Pubmed]
  4. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Van Rompay, K.K., Durand-Gasselin, L., Brignolo, L.L., Ray, A.S., Abel, K., Cihlar, T., Spinner, A., Jerome, C., Moore, J., Kearney, B.P., Marthas, M.L., Reiser, H., Bischofberger, N. Antimicrob. Agents Chemother. (2008) [Pubmed]
  5. Empowering the people: development of an HIV peer education model for low literacy rural communities in India. Van Rompay, K.K., Madhivanan, P., Rafiq, M., Krupp, K., Chakrapani, V., Selvam, D. Hum. Resour. Health (2008) [Pubmed]
  6. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Van Rompay, K.K., Johnson, J.A., Blackwood, E.J., Singh, R.P., Lipscomb, J., Matthews, T.B., Marthas, M.L., Pedersen, N.C., Bischofberger, N., Heneine, W., North, T.W. Retrovirology (2007) [Pubmed]
  7. Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. Van Rompay, K.K., Kearney, B.P., Sexton, J.J., Colón, R., Lawson, J.R., Blackwood, E.J., Lee, W.A., Bischofberger, N., Marthas, M.L. J. Acquir. Immune Defic. Syndr. (2006) [Pubmed]
  8. Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11. Van Rompay, K.K., Blackwood, E.J., Landucci, G., Forthal, D., Marthas, M.L. Virol. J. (2006) [Pubmed]
  9. Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. Van Rompay, K.K., Singh, R.P., Heneine, W., Johnson, J.A., Montefiori, D.C., Bischofberger, N., Marthas, M.L. J. Virol. (2006) [Pubmed]
  10. Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques. Van Rompay, K.K., Hamilton, M., Kearney, B., Bischofberger, N. Antimicrob. Agents Chemother. (2005) [Pubmed]
  11. Antiretroviral drug studies in nonhuman primates: a valid animal model for innovative drug efficacy and pathogenesis experiments. Van Rompay, K.K. AIDS. Rev (2005) [Pubmed]
  12. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Van Rompay, K.K., Brignolo, L.L., Meyer, D.J., Jerome, C., Tarara, R., Spinner, A., Hamilton, M., Hirst, L.L., Bennett, D.R., Canfield, D.R., Dearman, T.G., Von Morgenland, W., Allen, P.C., Valverde, C., Castillo, A.B., Martin, R.B., Samii, V.F., Bendele, R., Desjardins, J., Marthas, M.L., Pedersen, N.C., Bischofberger, N. Antimicrob. Agents Chemother. (2004) [Pubmed]
  13. CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. Van Rompay, K.K., Singh, R.P., Pahar, B., Sodora, D.L., Wingfield, C., Lawson, J.R., Marthas, M.L., Bischofberger, N. J. Virol. (2004) [Pubmed]
  14. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters. Van Rompay, K.K., Singh, R.P., Brignolo, L.L., Lawson, J.R., Schmidt, K.A., Pahar, B., Canfield, D.R., Tarara, R.P., Sodora, D.L., Bischofberger, N., Marthas, M.L. J. Acquir. Immune Defic. Syndr. (2004) [Pubmed]
  15. Tenofovir primes rhesus macaque cells in vitro for enhanced interleukin-12 secretion. Van Rompay, K.K., Marthas, M.L., Bischofberger, N. Antiviral Res. (2004) [Pubmed]
  16. Motor-biking through rural India on an HIV mission. Van Rompay, K.K. AIDS (2004) [Pubmed]
  17. Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus. Van Rompay, K.K., Schmidt, K.A., Lawson, J.R., Singh, R., Bischofberger, N., Marthas, M.L. J. Infect. Dis. (2002) [Pubmed]
  18. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. Van Rompay, K.K., McChesney, M.B., Aguirre, N.L., Schmidt, K.A., Bischofberger, N., Marthas, M.L. J. Infect. Dis. (2001) [Pubmed]
  19. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. Van Rompay, K.K., Miller, M.D., Marthas, M.L., Margot, N.A., Dailey, P.J., Canfield, D.R., Tarara, R.P., Cherrington, J.M., Aguirre, N.L., Bischofberger, N., Pedersen, N.C. J. Virol. (2000) [Pubmed]
  20. 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA. Van Rompay, K.K., Cherrington, J.M., Marthas, M.L., Lamy, P.D., Dailey, P.J., Canfield, D.R., Tarara, R.P., Bischofberger, N., Pedersen, N.C. Antimicrob. Agents Chemother. (1999) [Pubmed]
  21. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. Van Rompay, K.K., Marthas, M.L., Lifson, J.D., Berardi, C.J., Vasquez, G.M., Agatep, E., Dehqanzada, Z.A., Cundy, K.C., Bischofberger, N., Pedersen, N.C. AIDS Res. Hum. Retroviruses (1998) [Pubmed]
  22. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Van Rompay, K.K., Cherrington, J.M., Marthas, M.L., Berardi, C.J., Mulato, A.S., Spinner, A., Tarara, R.P., Canfield, D.R., Telm, S., Bischofberger, N., Pedersen, N.C. Antimicrob. Agents Chemother. (1996) [Pubmed]
 
WikiGenes - Universities